首页 | 本学科首页   官方微博 | 高级检索  
检索        


Current and future challenges in HCV: insights from an Italian experts panel
Authors:Massimo Andreoni  Sergio Babudieri  Savino Bruno  Massimo Colombo  Anna L Zignego  Vito Di Marco  Giovanni Di Perri  Carlo F Perno  Massimo Puoti  Gloria Taliani  Erica Villa  Antonio Craxì
Institution:1.Infectious Diseases, Polyclinic of Rome Tor Vergata,Rome,Italy;2.Infectious Diseases Unit, Department of Clinical and Experimental Medicine,University of Sassari,Sassari,Italy;3.Humanitas University and Humanitas Research Hospital,Rozzano,Italy;4.Humanitas Clinical and Research Center,Humanitas Research Hospital,Rozzano,Italy;5.Department of Experimental and Clinical Medicine, Interdepartmental Centre MASVE,University of Florence,Florence,Italy;6.Sezione di Gastroenterologia e Epatologia, DiBiMIS,University of Palermo,Palermo,Italy;7.Unit of Infectious Diseases, Department of Medical Sciences,Amedeo di Savoia Hospital, University of Turin,Turin,Italy;8.Department of Experimental Medicine and Surgery,University of Rome Tor Vergata,Rome,Italy;9.Infectious and Tropical Diseases Unit,Umberto I Hospital-“Sapienza” University,Rome,Italy;10.Department of Internal Medicine, Gastroenterology Unit,Azienda Ospedaliero-Universitaria Policlinico di Modena,Modena,Italy;11.Gastroenterology and Liver Unit, DiBiMIS,University of Palermo,Palermo,Italy
Abstract:

Background

The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages.

Methods

A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens.

Results and conclusions

Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号